
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen is positioned for a positive growth trajectory, as recent product launches like Leqembi, Skyclarys, and Zurzuvae have surpassed consensus expectations, indicating strong commercial execution. Despite expectations of revenue growth not materializing until 2026, management is focused on strategic business development initiatives that are anticipated to drive near-term earnings upside. With projections suggesting that key product launches could generate $2.5 to $3.0 billion in revenue by 2030, Biogen's robust pipeline and ability to address market bottlenecks present significant long-term growth potential.
Bears say
Biogen's reliance on its declining multiple sclerosis franchise, which accounted for 45% of total revenue in 2024, raises concerns about the sustainability of its revenue streams. Additionally, while the company generates substantial income from CD20 collaboration agreements with Roche, contributing 18% of total revenue, the overall dependence on a limited product portfolio can create vulnerability to market fluctuations. Furthermore, with a focus on newer franchises that may not yet have established significant market traction, Biogen's future revenue growth prospects appear uncertain, adding to the negative outlook.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares